Skip to main
STRO
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 23%
Hold 23%
Sell 8%
Strong Sell 0%

Bulls say

Sutro Biopharma Inc. has demonstrated promising advancements in its product pipeline, particularly with STRO-004 showcasing improved safety and anti-tumor activity compared to existing treatments, which supports a strong potential for clinical success. The company is undergoing a significant workforce reduction of approximately 50% and will externalize its cell-free manufacturing capabilities, aligning with a strategy aimed at long-term growth and financial sustainability through 2026. Furthermore, the anticipated decrease in operating expenses by 50-70%, along with innovative product characteristics, positions Sutro favorably within the biopharmaceutical sector.

Bears say

Sutro Biopharma faces significant risks impacting its financial outlook, primarily stemming from potential underperformance of its lead antibody-drug conjugate (ADC) candidates, which could lead to reduced market penetration and longer timelines for drug approvals. The company reported a net loss of $227.4 million for FY24, equating to a loss of $2.96 per share, and its cash reserves decreased from $388.3 million to $316.9 million within a three-month period, indicating possible liquidity concerns amid ongoing developmental challenges. Additionally, the decision to implement a near-50% headcount reduction and the discontinuation of the luvelta program, once a pivotal aspect of Sutro's portfolio, raises further doubts about the company’s strategic direction and ability to deliver value to shareholders.

STRO has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 13 analysts, STRO has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.